Valuation: Zeo ScientifiX, Inc.

Market Cap 16.46M 14.4M 13.28M 12.26M 23.27M 1.57B 23.66M 159M 62.31M 773M 61.8M 60.45M 2.66B P/E 2024
-2.29x
P/E 2025 -2.17x
Enterprise Value 16.59M 14.51M 13.39M 12.36M 23.46M 1.58B 23.85M 160M 62.81M 779M 62.29M 60.94M 2.68B EV / Sales 2024
2.43x
EV / Sales 2025 2.45x
Free-Float
64.39%
Yield 2024 *
-
Yield 2025 -
06-16 Zeo ScientifiX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 CI
06-09 Zeo Scientifix, Inc. Announces Management Changes CI
04-09 Zeo Scientifix Inc - enters MoU with Regen Therapy for exclusive scientific and biologics collaboration - SEC filing RE
04-09 Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics-Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO Scientifix CI
03-28 Zeo Scientifix, Inc. Announces Termination of Dr. John D. Kisiday as Chief Science Officer Effective March 23, 2026 CI
03-18 Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 CI
01-30 Zeo ScientifiX, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 CI
01-29 Zeo ScientifiX, Inc. Auditor Raises 'Going Concern' Doubt CI
01-28 Zeo Scientifix, Inc. Appoints John D. Kisiday as Chief Science Officer, Effective January 23, 2026 CI
01-07 Cytora Therapeutics, Made Scientific, and Zeo Scientifix Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States CI
01-07 Cytora Therapeutics partners with Made Scientific, and Zeo Scientifix to manufacture allogeneic stem cell therapy RE
01-05 Zeo ScientifiX, Inc. Appoints Ian T. Bothwell as Full-Time Chief Executive Officer, Effective December 24, 2025 CI
12-04 Zeo Scientifix, Inc. Terminates Ron Borsheim as Chief Sales Officer Aesthetics, Effective November 30, 2025 CI
1 day+10.82%
1 week+10.53%
Current month+17.98%
1 month+16.67%
3 months+6.33%
6 months-19.23%
Current year-22.51%
1 week 1.68
Extreme 1.68
2.18
1 month 1.32
Extreme 1.32
2.18
Current year 1.32
Extreme 1.32
2.98
1 year 1.2
Extreme 1.2
2.99
3 years 0.8
Extreme 0.8
4.8
5 years 0.8
Extreme 0.8
33.98
10 years 0.7
Extreme 0.7
125.98
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2024
Chief Tech/Sci/R&D Officer - 01/01/2020
Compliance Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 65 11/09/2019
Director/Board Member 78 23/09/2022
Director/Board Member 64 19/08/2022
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Chief Technology Officer

1,250,000 16.0721%
06-10
Greyt Ventures LLC
FreeCompany 1,250,000 16.0721%
06-10Free

Chairman

80,000 1.0286%
Change 5-day change 1-year change 3-year change Capi.($)
+10.82%+10.53%+12.30%+2.44% 14.85M
+1.66%+2.50%+12.79%+94.32% 92.82B
+0.87%-1.31%+45.40%+151.68% 54.75B
-1.74%+1.08%-1.05%+256.96% 22.92B
+0.37%+0.06%-13.74%-24.70% 7.97B
+1.98%-2.23%-26.26%-33.33% 7.43B
+0.42%-0.06%-10.63%-29.41% 6.63B
-1.16%-1.48%+23.13%+31.93% 6.31B
-0.23%+0.41%-1.70%+22.88% 5.37B
+0.20%+1.42%-5.83%-8.33% 3.67B
Average +1.32%+0.73%+3.44%+46.44% 20.79B
Weighted average by Cap. +0.84%+0.13%+16.30%+108.72%

Financials

2024 2025
Net sales 4.62M 4.04M 3.73M 3.44M 6.53M 441M 6.64M 44.54M 17.49M 217M 17.35M 16.97M 746M 5.2M 4.55M 4.19M 3.87M 7.35M 496M 7.47M 50.12M 19.68M 244M 19.52M 19.1M 840M
Net income -4.7M -4.12M -3.8M -3.51M -6.65M -449M -6.76M -45.36M -17.81M -221M -17.67M -17.28M -760M -5.52M -4.83M -4.45M -4.11M -7.81M -527M -7.94M -53.22M -20.9M -259M -20.73M -20.28M -892M
Net Debt 36K 31.49K 29.04K 26.83K 50.9K 3.43M 51.76K 347K 136K 1.69M 135K 132K 5.81M 132K 115K 106K 98.36K 187K 12.59M 190K 1.27M 500K 6.2M 496K 485K 21.32M
Logo Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. Its proprietary products, including Zofin, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. It has developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.
Employees
20
Date Price Change Volume
10/07/26 $2.100 +10.82% 11,048
09/07/26 $1.895 +5.28% 4,625
08/07/26 $1.800 +1.83% 4,877
07/07/26 $1.768 -2.34% 578
06/07/26 $1.810 -4.74% 5,011
  1. Stock Market
  2. Stocks
  3. ZEOX Stock